A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects.
- DOI
- 10.3389/fphar.2023.1296672
- Published
- 2023
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2023.1296672,
title = {A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects.},
author = {Chen Q and Wu Q and Song R and Wang Y and Zhang M and Li F and Zeng W and Wang W and Jia J and Yu C and Liu Y},
year = {2023},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2023.1296672},
url = {https://doi.org/10.3389/fphar.2023.1296672}
}RIS
TY - JOUR TI - A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects. AU - Chen Q AU - Wu Q AU - Song R AU - Wang Y AU - Zhang M AU - Li F AU - Zeng W AU - Wang W AU - Jia J AU - Yu C AU - Liu Y PY - 2023 JO - Frontiers in pharmacology DO - 10.3389/fphar.2023.1296672 UR - https://doi.org/10.3389/fphar.2023.1296672 ER -
APA
Q, C., Q, W., R, S., Y, W., M, Z., F, L., W, Z., W, W., J, J., C, Y., & Y, L. (2023). A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2023.1296672
Source records
- pubmed · retrieved 2026-09-27T09:36:45.805Z